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De novo membranous nephropathy in human renal allografts: Report
of nine patients. Nine new patients with de novo membranous nephrop-
athy (MN) are reported. The onset of MN, as defined by onset of
nephrotic-range proteinuria, ranged from II to 30 months after trans-
plantation. Five of the nine patients returned to hemodialysis within 4 to
26 months after the onset of nephrotic syndrome. No known exogenous
(for example, ALS or HB..Ag) or endogenous antigens could be
demonstrated as the cause in any of the nine patients. The possibility
that excellent tissue compatibility might increase the risk of subsequent
de novo MN is suggested by the finding of four patients with "full
house" HLA-A,B matches, two with none, and two with only one
HLA-A,B mismatch. This phenomenon occurs in approximately one in
100 to 200 transplants. It is suggested that de novo MN is not as unusual
as heretofore believed and that its prognosis is poor.
Néphropathie extramembraneuse de novo sur des greffons rénaux
humains; Ranport de neuf malades. Neuf nouveaux malades avec
néphropathie extramembraneuse de novo (MN) sont rapportés. La date
d'apparition d'une MN, définie par lapparition d'une protéinurie
abondante, était comprise entre 11 et 30 mois après transplantation.
Cinq des neuf malades sont retournés en hémodialyse 4 a 26 mois après
l'apparition du syndrome néphrotique. Aucun antigene connu exogéne
(par exemple, ALS ou HBAg) ou endogéne n'a pu ëtre impliqué chez
aucun des neuf malades. La possibilité qu'une excellente compatibilité
tissulaire augmente Ic risque d'apparition ultérieure d'une MN de novo
est suggérée par le fait que quatre malades sont HLA-A,B identiques,
deux n'ont pas, et deux n'ont qu'une incompatibilité dans le système
HLA-A,B. Ce phenomene survient chez approximativement un pour
100 ou 200 transplants. II est suggéré que Ia MN de novo n'est pas aussi
inhabituelle qu'on le pensait jusqu'ici et que son pronostic est
défavorable.
The development of glomerulonephritis in the transplanted
kidney has been recognized for several years 11—5]. Most of
these lesions comprise recurrent illness due to presumed per-
sistent nephritogenic stimuli [31 or so-called transplant glomeru-
lopathy [1]. Comparatively few cases reported, however, repre-
sent de novo glomerulonephritis in patients demonstrated to
have had other types of glomerulonephritis or nonimmunologi-
cally mediated renal disease as their original problem. The
literature contains approximately 20 patient reports of de novo
membranous nephropathy; these 20 patients account for the
majority of these episodes [6—18]. We report nine patients,
seven from one center, Université Catholique de Louvain,
Brussels, Belgium (UCL), who developed "de novo" membra-
nous nephropathy in a transplanted kidney.
Methods
Patient population. Between November 1, 1966, and July 31,
1980, 851 renal allografts were performed at UCL; of these, 119
were from living donors and 732 were from cadavers; 676 of the
grafts lasted over 3 months. Of the 115 renal transplants carried
out at Tufts-New England Medical Center, Boston, Massachu-
setts, (T-NEMC) over the last 10 years, 53 were from living
donors and 62 were from cadavers. All patients were treated
with conventional immunosuppressive regimens consisting pri-
marily of azathioprine and steroids; additionally, antilympho-
cyte serum (ALS) was administered to all patients transplanted
at UCL in the last 4 years (388 patients). One patient (patient
no. 3) from Bay State Medical Center was treated with predni-
sone, azathioprine, and a 14-day course of an intravenous F'AB
fragment of pooled anti-HLA antibody. Acute rejection was
treated with either higher doses of oral prednisolone or "pulse"
injections of prednisolone. Additionally, rejection crises at
UCL were treated by local graft irradiation, and more recently,
by a 10-day course of intravenous ALS. All patients had a
negative crossmatch just prior to transplantation. The original
renal disease was diagnosed pathologically in six patients and
by clinical and radiologic criteria in the remaining three patients
(Table 1). Standard histologic and radioimmunoassay tech-
niques were used.
Diagnosis of de novo membranous nephropathy. To establish
a diagnosis of de novo membranous nephropathy (MN) in the
transplanted kidney, there must be sufficient clinical and/or
pathologic data to exclude the diagnosis of membranous
nephropathy as the cause of the original renal disease. Further,
the glomerular histology of the transplanted kidney must meet
the usual criteria for the diagnosis of membranous nephropathy
177
Received for publication March 31, 1981
and in revised form February 22, 1982
0085—2538/82/0022—0 177 $01.40
© 1982 by the International Society of Nephrology
178 Cosyns et a!
Table 1. Pathologic data
I Reflux
nephropathy
2 Chronic interstitial
nephritis
3 Membranoproliferative
GN, type I
4 Polycystic kidney
disease
5 Oxalosis
6 Focal
glomerulosclerosis
7 Chronic
glomerulonephritis
8 Chronic interstitial
nephritis
9 Chronic pyelonephritis
Patient
no.
Biopsies
time
post-TP
Donor
30 months
6 months
8 months
4days 0
14 days
24 months
24 months
13 months
25 months
13 months
25 months
59 months
Nephrotic syndrome
Time Serum
post-TP creatinine
months mg/dl
30
11
24
24
25
25
24
29
17
Tubular
atrophy and
interstitial
fibrosis
++ 0
++ ++
+++
0
0
0
+
++
+++
0
++
++
Abbreviations: HD, hemodialysis; TP, transplant.
in the nontranspianted patient 1191. These criteria include: (1)
the presence of diffuse glomerular capillary basement mem-
brane thickening with the characteristic basement membrane
projections demonstrated by silver stains; or (2) a glomerular
basement membrane appearing normal by light microscopy but
which can be confirmed via immunofluorescent studies to be
membranous nephropathy by the demonstration of diffuse
granular deposition of immunoglobulin (IgG), often with com-
plement (C3), along glomerular basement membranes; or (3) the
demr'-istration by electron microscopy of diffuse subepithelial
electron-dense deposits along glomerular capillary basement
membranes. Transplant glomerulopathy also should be exclud-
ed 1201 and, when possible, a biopsy specimen or careful review
of the pertinent clinical information from the donor should
exclude the possibility of membranous nephropathy being pres-
ent in the graft at the time of transplantation. None of the
donors in the present series had proteinuria.
Patient material. Results of the pathologic findings that
document de novo membranous nephropathy are summarized
in Table 1. Clinical data from the nine patients are summarized
in Table 2. (The subsequent course of patient no. 6 is reported
in detail elsewhere [211.)
Patient
no.
Dc novo membranous nephropathy
glomerular evaluation
Original disease
IFr
LMb
0
+
0
+
Rejection lesionsC
lgG 1gM IgA
0 0 0
4+ 2+ 0
2+ 0 0
3+ 0 0
C Clq C4 Fibrin EM4
Chronic
vascular
rejection000 0 0
3+ — 2+ 1+ 2to300 — 0
2+ 1+ — 0 2
Chronic
transplant
glomerulopathy
0 0
+ 0
+ 0
+ 0
0 0
0
0
0
+
— 0
2 ++
0
0
0 3+ 0 0 0 — — 0
0 0 0 0 0 — — 0
+ 3+ 0 0 2+ — — 0
+
++ — —
0
0
0
+ ++ 0
2 + ++ ++
+++ +++ +++
27 months + 3+ 2+ 0 0 0 — 0 2 + 0
29 months + 3+ 0 0 1 + I+ — 1) 1 ++ 0
17 months + 3+ 2+ 2+ 2+ 2+ — 0 I + +
Transplant (TP) lesions were graded as absent (0), mild (+), moderate (++), or severe (+++) [20].
b LM refers to light microscopy. Membranous nephropathy was present (+) or absent (0) according to the criteria in Methods.
IF refers to immunofluorescence. Deposits were graded as absent (0), doubtful (1+), weak (2+), moderate (3+), and bright (4+). In some
patients, IF was not performed (—).
EM refers to electron microscopy. Staging was carried out using criteria of Ehrenreich et al [19]. In some patients, the lesion was absent (0), or
EM was not performed (—).
Table 2. De novo membranous nephropathy
Onset proteinuria
Time Serum
Donor post-TP creatinine
Sex/Age source months mg/dl
1 M 24 Sibling 2 1.5
2 F27 Cadaver 6 1.1
3 F 36 Cadaver 2 1.7 to 1.9
4 F 39 Cadaver 19 0.8
5 M 19 Cadaver 15 1.8
6 F 23 Cadaver 3 1.0
7 F 39 Cadaver 17 0.9
8 F 17 Sibling 11 0.8
9 M 35 Cadaver 4 1.3
Clinical course
4.7 Return HD 34 months post-TP
1.0 Serum creatinine 1.1 mg/dl at 21 months
2.2 Return HD 36 months post-TP
0.8 Return HD 50 months post-TP
2.7 Return HD 30 months post-TP
1.9 Return HD 51 months post-TP
0.9 Serum creatinine 0.9 mg/dl at 28 months
0.8 Serum creatinine 0.8 mg/dl at 32 months
1.4 Serum creatinine 1.4 mg/dl at 20 months
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Fig. I. Renal graft biopsy specimen 30 months of
ter transplantation. A. Silver stain with extensive
subepithelial basement membrane projections.
(x450) B Immunofluorescence showing diffuse
granular deposition of IgG along glomerular capil-
lary basement membranes, (x410) C Electron mi-
crograph showing diffuse subepithelial electron-
dense deposits with basement membrane projec-
tions both between ( spikes") and around
("domes") deposits (X3500).
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Illustrative case reports
Patient 1. A 24-year-old man developed endstage renal failure
as a result of congenital obstructive uropathy. Hemodialysis
was begun at age 16 years and bilateral nephrectomy was
performed. The kidneys were both small (left, 17 g; right, 25 g),
with moderate to severe hydronephrosis bilaterally. In addition
to focal glomerular scarring and tubular atrophy, both kidneys
displayed segmental dysplasia. The preserved glomeruli were
not remarkable by light microscopy, which included a silver
stain of the basement membrane.
At age 17 years, he received his first cadaveric transplant.
The graft, removed alter 15 days of oliguria, showed only
hemorrhagic necrosis of both the cortex and medulla. At age 20
years, he received a second cadaveric transplant. A biopsy
performed 1 hr post-transplantation contained fibrin deposits in
some glomerular capillary lumina and suggested hyperacute
rejection, The rejected kidney was removed on day 47; patho-
logic examination demonstrated interstitial rejection as well as
proliferative and necrotizing vascular lesions with diffuse hem-
orrhagic necrosis and focal infarction. Immunofluorescent stud-
ies demonstrated only focal glomerular deposition of 1gM. One
year later, the patient had HBAg-negative hepatitis that re-
solved spontaneously.
At age 21 years, he received a third HLA-identical transplant
from his brother. The 1-hr post-transplantation biopsy speci-
men was unremarkable by tight, electron, and immunofluores-
cence microscopy. The 24-hr urine protein excretion was 80 to
110 mg in the immediate post-transplant period but 1.5 g 2
months following transplantation.
For the next 2 years, the patient excreted 1 to 3 glday of
protein; the serum creatinine remained stable in the range of 1 .5
to 2.2 mg/dl. Twenty-eight months after transplantation a
retrograde urogram revealed obstruction of the transplanted
*%$?A ZjTh -. V'fr '
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Fig. 2. Renal graft biopsy specimen 6 nonths after transplantation; capillary loop with rare subepithelial electron dense deposits (center) (EM
x 13,600).
kidney at the ureteropelvic junction. The patient underwent a
ureteropyeloplasty; a renal biopsy was performed during the
operative procedure (Fig. I). There were mild to moderate
chronic rejection lesions and membranous nephropathy; the
MN was diagnosed by the finding of basement membrane
projections on light microscopy (silver stain); IgG with C3, 1gM,
C4, and fibrinogen on immunofluorescence; and diffuse subepi-
thelial deposits on electron microscopy. Renal function contin-
ued to deteriorate, and dialysis was reinitiated when the serum
creatinine level reached 10.5 mg/dl.
Patient 2. A 27-year-old woman received a cadaver graft after
3 years of hemodialysis for chronic interstitial nephritis. Native
kidney biopsy performed during transplantation contained a
few hyalinized glomeruli and 11 glomeruli that were either
normal or ischemic with a fibrous, thickened Bowman's cap-
sule. Well-preserved tubules filled with polymorphonuclear
leukocytes were adjacent to several interstitial scars. The
interstitium was infiltrated with round cells, polymorphonucle-
ar leukocytes and rare foam cells; minimal intimal thickening of
the arterioles was observed. No IgG, IgA, 1gM, C, or fibrino-
gen was detected by immunofluorescence. Electron microsco-
py revealed no subepithelial glomerular deposits. The diagnosis
of chronic interstitial nephritis was confirmed. An acute rejec-
tion episode was reversed successfully on the 50th day. Six
months after transplantation, severe arterial hypertension and
moderate proteinuria (2 g/liter) had developed. Angiography
disclosed an 80 to 90% stenosis of the initial segment of the graft
renal artery. A graft biopsy performed at this time disclosed
stage 1 membranous nephropathy [19]; the diagnosis was made
by the finding of lgG on immunofluorescence and subepithelial
deposits on electron microscopy (Fig. 2).
The arterial stenosis was corrected with a saphenous graft 2
months later. Both HBAg and anti-HBs antibody were absent
in the serum. A second renal biopsy was performed then. Mild
chronic rejection lesions were present as was stage 2 membra-
nous nephropathy [19]; the diagnosis was made by the finding of
spikes on light microscopy (silver stain), IgG with C3 and CIq on
immunofluorescence, and multiple subepithelial deposits on
electron microscopy. Twenty-one months after transplantation,
nephrotic-range proteinuria persisted, but the serum creatinine
concentration remained normal (1.1 mg/dl).
Discussion
The diagnosis of de novo membranous nephropathy in the
nine renal allografts appears well founded (Tables I and 2). In
seven instances, the diagnosis was established on the basis of
the typical immunofluorescence findings observed in idiopathic
membranous nephropathy in nontransplant recipients; in six of
these seven grafts, characteristic electron microscopic findings
of membranous nephropathy also were demonstrated. In the
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two patients in whom immunofluorescence microscopy was not
available, membranous nephropathy was diagnosed by light and
electron microscopy in one and by electron microscopy in the
other (Table 1).
To prove that these instances of membranous nephropathy
are indeed de novo membranous nephropathy and not recurrent
disease, it is imperative that sufficient clinical and pathologic
data be available so that the possibility that membranous
nephropathy caused the original renal disease can be eliminat-
ed. In six of our patients, the "de novo" character of membra-
nous nephropathy rests on well-documented histologic evi-
dence of the initial renal disease. In the three patients in whom
histology documenting the nature of the original renal disease
was unavailable, polycystic kidney disease was diagnosed
clinically and radiologically in one (patient no. 4), oxalosis was
diagnosed clinically in another (patient no. 5), and chronic
pyelonephritis was diagnosed radiologically in the patient with a
horseshoe kidney (patient no. 9).
Natural history. In contrast to the slowly progressive course
over years of idiopathic membranous nephropathy in nontrans-
planted patients [22, 231, once the nephrotic syndrome devel-
oped in our nine patients, renal function deteriorated inexorably
and rapidly in five and led to resumption of hemodialysis only 4
to 26 months later (Table 2). In the four other patients, renal
function remains stable 3 to 10 months after the onset of
nephrotic syndrome. Again, in contrast to idiopathic membra-
nous nephropathy in the nontransplant setting, no spontaneous
recovery from the nephrotic syndrome has been observed in
these nine patients. The limited information regarding the
clinical course of de novo membranous nephropathy available
[6—18] suggests that the evolution of de novc membranous
nephropathy in transplant recipients is not as favorable as was
believed previously [14]. The prognosis therefore appears much
worse than that of idiopathic membranous nephropathy, per-
haps as a result of superimposed glomerular and interstitial
lesions associated with chronic rejection.
Pathogenesis. The pathogenesis of human membranous
nephropathy remains controversial. At least three different
mechanisms have been postulated [24—31]: (1) in situ immune
complex formation of exogenous antigen and circulating anti-
body in the subepithelial space; (2) the binding of free circulat-
ing antibody to a fixed antigen, endogenous to the glomerulus;
and (3) passive trapping in the glomerular basement membrane
of small-sized circulating immune complexes, the latter result-
ing from a poor to moderate antibody response to antigenic
stimulation. All three of these postulated mechanisms involve
an inciting antigen and an antibody response. The responsible
antigen may be either exogenous or endogenous. First, we will
discuss the antigens that might be involved and then discuss
how the antibody response might be modified, thereby leading
to the development of membranous nephropathy.
Various exogenous antigens have been identified or suspect-
ed in idiopathic membranous nephropathy in nontransplanted
patients [22]. Hepatitis B viral infection (HBV) has been
suspected on the basis of a strong association between membra-
nous nephropathy and HBs antigenemia [32. 33]. Further,
HBAg has been demonstrated in extramembranous immune
deposits in some patients with idiopathic membranous nephrop-
athy [34—37]. In two of our patients, HBAg was positive in the
serum but was not found in the graft biopsy specimen. Thus,
it is unlikely that HBV is the responsible agent, although this
possibility cannot be excluded [38]. In the seven other patients,
HBAg was absent from serum when the de novo membranous
nephropathy was identified. The ALS, an exogenous antigen
utilized in the treatment of some transplanted patients, theoreti-
cally could cause membranous nephropathy. Glomerular le-
sions associated with the deposition of horse lgG have been
reported after ALS administration [39], but the lesions did not
include the typical deposits of membranous nephropathy. In six
of our patients treated with ALS, no horse IgG could be
detected in the graft by direct and indirect immunofluores-
cence. In the three other patients, de novo membranous
nephropathy developed although ALS had never been given.
None of our patients received any drug or had any other
systemic disease known to be associated with membranous
nephropathy. Although several tumor antigens have been impli-
cated in the genesis of idiopathic membranous nephropathy
[40—41], basal cell carcinoma of the skin, which developed in
patient no. 4, has not been observed previously.
The kidney graft could be the source of fixed endogenous
antigens, which might be released as a result of damage from
vesicoureteral reflux. This mechanism has been invoked to
account for diverse glomerular lesions [42—43]; in one patient,
idiopathic membranous nephropathy was described in associa-
tion with refiux [44]. Reflux was absent, however, in our four
patients in whom micturating cystography was performed. The
graft antigens, for example, a tubular alloantigen [30], also
could be released because of ischemic injury [45] (such as that
observed in patient no. 2 who had renal artery stenosis),
recurrence of a systemic disease such as oxalosis (patient no.
5), or the rejection process. In agreement with this last hypothe-
sis is the fact that all biopsy specimens showed diffuse intersti-
tial fibrosis, a lesion common in chronic transplant rejection but
relatively unusual in idiopathic membranous nephropathy [46].
This hypothesis could be substantiated by the identification of
offending renal antigens, but verification has been attempted in
only two reported patients in whom the search for antibrush-
border antibodies was negative [6, 8].
A poor to moderate antibody response can contribute to the
development of de novo membranous nephropathy. Theoreti-
cally this could happen because of any one of several mecha-
nisms. The first is a genetically determined impaired state of
immune responsiveness [47]. Klouda et al reported a strong
association between idiopathic membranous nephropathy and
HLA-DRW3 [48]. None of our four patients in whom DR typing
was available had this antigen. By contrast, in our nine patients
in whom adequate data are available, five had the BW 35
antigen. Our group is too small, however, for us to draw a
conclusion regarding the significance of this observation. A
second possible mechanism is the effect of immunosuppressive
agents. By decreasing antibody synthesis and producing antigen
excess, localization of the complexes may be affected [49, 50].
Third, a poor or moderate immune response in our patients also
might be related to the excellent histocompatibility. It is striking
that in our population, de novo membranous nephropathy
seemed to develop in well-matched kidneys. Indeed, in our nine
patients with de novo membranous nephropathy in which data
for HLA-A and B antigens are available, four had "full house"
HLA-A,B matches, two had none, and two had only one HLA-
A,B mismatch. If good histocompatibility favors the onset of de
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novo membranous nephropathy, as appears to be the case in
some experimental settings [30], it might be anticipated that the
prevalence of de novo membranous nephropathy will vary from
one series to another, being higher in series such as ours with a
high degree of histocompatibility. In the UCL experience, the
average number of HLA mismatches was very low; the mean
number of HLA-A,B mismatches in a group of primary cadaver
grafts was approximately 1.0 [51].
Finally, it should be noted that the prevalence of de novo
membranous glomerulonephritis might he higher than previous-
ly assumed. Seven cases have been observed in a series of 851
transplants performed at UCL between November 1, 1966, and
July 31, 1980; 676 of these grafts lasted for more than 3 months
(that is, approximately 1 in 100 transplants). It thus seems likely
that more cases of de novo membranous nephropathy will be
observed as the worldwide pool of transplant patients gradually
enlarges.
Note added in proof
In addition to the references listed below, we suggest an
important new paper bearing on the subject:
CHARPENTIER B, Lcvv M, G.C.1.F.: Etude cooperative des glomCru-
lonephrites extramembraneuses de novo" sur allogreffe rCnale hu-
maine: Rapport de 19 nouveaux cas sur 1550 transplantCs rénaux du
groupe de transplantation de llle de France (G.C.1.F.). Néphrologie 3,
in press. 1982
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